Simvastatine

PreclinicalSmall molecule

TTel-Aviv Sourasky Medical Center

Simvastatine is one of 4 small molecule programs targeting Pachyonychia Congenita. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pachyonychia CongenitaActive, not recruiting

Pachyonychia CongenitaPreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Pachyonychia Congenita

#DrugCompanyPhaseTrials

Rapamune

PPrism Pharmaceuticals

Approved

—2

PTX-022

PPalvella Therapeutics, Inc.

Phase 3

3 3

Zocor

OOrganon and Co

Preclinical

—4

Simvastatine

TTel-Aviv Sourasky Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

The Effect of High Dose Simvastatine on Multiple Myeloma

Completed·VVejle Hospital·Phase 1/2·NCT00281476·10 enrolled

Pachyonychia Congenita1 trial

Simvastatin Treatment of Pachyonychia Congenita

Unknown status·TTel-Aviv Sourasky Medical Center·N/A·NCT01382511·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Simvastatine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Simvastatine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Simvastatine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tel-Aviv Sourasky Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTel-Aviv Sourasky Medical Center

Simvastatine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Myeloma1 trial

Pachyonychia Congenita1 trial

References

Drug Info

Quick Facts

Related News